Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial.
Metra M, Mentz RJ, Chiswell K, Bloomfield DM, Cleland JG, Cotter G, Davison BA, Dittrich HC, Fiuzat M, Givertz MM, Lazzarini V, Mansoor GA, Massie BM, Ponikowski P, Teerlink JR, Voors AA, O'Connor CM. Metra M, et al. Among authors: cotter g. Eur J Heart Fail. 2015 Jan;17(1):109-18. doi: 10.1002/ejhf.207. Epub 2014 Nov 27. Eur J Heart Fail. 2015. PMID: 25431336 Free article. Clinical Trial.
Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.
Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A, Jafari J, Reisin L, Krakover R, Vered Z, Caspi A. Cotter G, et al. Eur J Heart Fail. 2001 Aug;3(4):457-61. doi: 10.1016/s1388-9842(01)00168-4. Eur J Heart Fail. 2001. PMID: 11511432 Free article. Clinical Trial.
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Torre-Amione G, et al. Among authors: cotter g. J Am Coll Cardiol. 2003 Jul 2;42(1):140-7. doi: 10.1016/s0735-1097(03)00556-4. J Am Coll Cardiol. 2003. PMID: 12849674 Free article. Clinical Trial.
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.
Cotter G, Kaluski E, Stangl K, Pacher R, Richter C, Milo-Cotter O, Perchenet L, Kobrin I, Kaplan S, Rainisio M, Frey A, Neuhart E, Vered Z, Dingemanse J, Torre-Amione G. Cotter G, et al. Eur J Heart Fail. 2004 Aug;6(5):601-9. doi: 10.1016/j.ejheart.2004.05.004. Eur J Heart Fail. 2004. PMID: 15302008 Free article. Clinical Trial.
Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome.
Uriel N, Torre-Amione G, Milo O, Kaluski E, Perchenet L, Blatt A, Kobrin I, Turnovski A, Kaplan S, Rainisio M, Frey A, Vered Z, Cotter G. Uriel N, et al. Among authors: cotter g. Eur J Heart Fail. 2005 Aug;7(5):815-9. doi: 10.1016/j.ejheart.2004.10.013. Eur J Heart Fail. 2005. PMID: 16087136 Free article.
332 results